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Abstract
 
The B lymphocyte–associated adaptor protein 32 kD in size (Bam32) is expressed at high levels
in germinal center (GC) B cells. It has an NH
 
2
 
-terminal src homology 2 (SH2) domain which
binds phospholipase C (PLC)
 
 
 
2, and a COOH-terminal pleckstrin homology (PH) domain.
Thus, Bam32 may function to integrate protein tyrosine kinase (PTK) and phosphatidylinositol
3-kinase (PI3K) signaling pathways in B cells. To further define the role Bam32 plays in B cells,
we generated Bam32-deficient DT40 cells. These Bam32
 
 
 
/
 
 
 
 cells exhibited lower levels of B
cell antigen receptor (BCR)-induced calcium mobilization with modest decreases in tyrosine
phosphorylation of phospholipase C (PLC)
 
 
 
2. Moreover, BCR-induced activation of extra-
cellular signal-regulated kinase (ERK), c-jun NH2-terminal kinase (JNK), and p38 mitogen-
activated protein kinase (MAPK) pathways was impaired in Bam32
 
 
 
/
 
 
 
 cells but not the activa-
tion of Akt-related pathways. Activation of downstream transcription factors such as nuclear
factor of activated T cells (NF-AT) and nuclear factor of 
 
 
 
 binding (NF-
 
 
 
B) was also impaired
in Bam32
 
 
 
/
 
 
 
 cells. Furthermore, Bam32
 
 
 
/
 
 
 
 cells were more susceptible to BCR-induced
death. Taken together, these findings suggest that Bam32 functions to regulate BCR-induced
signaling and cell survival most likely in germinal centers.
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Introduction
 
Signal transduction pathways initiated through the B cell
antigen receptor (BCR) complex determine the fate of B
cells depending on the context of Ag, expression levels of
coreceptors, and the differentiation stage of the B cell (1).
Upon BCR cross-linking, immature B cells undergo apop-
tosis or become anergized, while mature B cells enter the
 
cell cycle and differentiate into memory or antibody-secreting
plasma cells (2). BCR engagement induces the activation of
three distinct protein tyrosine kinases (PTKs): src-family
PTKs (such as Lyn), Syk, and Btk, which in turn regulate
several downstream signaling pathways. The significance of
these PTKs in B cell function has been underscored by
studies with genetically deficient animals or humans (1, 3).
In addition to PTKs, a growing family of immune cell–
restricted adaptors fine tune BCR signaling cascades (1). As
the expression levels of these adaptors change during B cell
differentiation, we postulated that B cell adaptors play piv-
otal roles in decisions affecting B cell fate (1).
Bam32, a B cell adaptor molecule 32 kD in size, was
originally identified during screens for genes highly ex-
pressed in human germinal center (GC) cells (4). Bam32
contains an NH2-terminal src homology 2 (SH2) domain,
one potential tyrosine phosphorylation site, and a COOH-
terminal pleckstrin homology (PH) domain but no appar-
ent catalytic domain. Bam32 was also identified by others
as a novel PH-domain containing adaptor protein desig-
nated dual adaptor for phosphotyrosine and 3-phosphoino-
sitides (DAPP1) or 3
 
 
 
-phosphoinositide-interacting src ho-
mology–containing protein (PHISH; references 5 and 6).
Based on its structure, Bam32 (DAPP1/PHISH) may
function to integrate PTK and phosphatidylinositol 3-kinase
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(PI3K) signaling pathways. Indeed, Bam32 is efficiently tar-
geted to the plasma membrane upon BCR cross-linking in
a PI3K-dependent manner (4). Given its preference and
high affinity for binding to PI(3,4,5)P3 (Bam32 
 
  
 
 Btk/
Akt; reference 5), Bam32 may be one of the first proteins
recruited to the plasma membrane after PI3K activation in
B cells. Bam32 also associates with several tyrosine-phos-
phorylated proteins after BCR cross-linking, including
phospholipase C (PLC)
 
 
 
2 (4).
To further define the role of this adaptor in B cells, we
prepared Bam32-deficient DT40 cells. We found that the
absence of Bam32 attenuates a number of BCR-induced
processes including activation of c-jun NH2-terminal ki-
nase (JNK) and nuclear factor of activated T cells (NF-AT)
and also increases BCR-induced cell death.
 
Materials and Methods
 
Reagents.
 
Mouse anti–chicken IgM (M4) mAb and rabbit
anti–chicken PLC
 
 
 
2 Ab were described previously (7). Rab-
bit anti–human phospho-extracellular signal-regulated kinase
(ERK), rabbit anti–rat ERK, rabbit anti–human phospho-JNK,
rabbit anti–human phospho-p38 mitogen-activated protein ki-
nase (MAPK), rabbit anti–mouse Akt phospho-serine 473-spe-
cific, rabbit anti–human phospho-Glycogen synthase kinase
(GSK)-3
 
 
 
/
 
 
 
, rabbit anti–mouse Akt, and rabbit anti–human
phospho-Mek1/2 sera were purchased from Cell Signaling Tech-
nology. Mouse anti–human JNK1 mAb was purchased from BD
PharMingen. Mouse anti–human c-Myc mAb (9E10) and rabbit
anti–mouse p38 MAPK sera were purchased from Santa Cruz
Biotechnology, Inc. Mouse anti–human Raf-1 phospho-serine
338-specific mAb and biotinylated anti-phosphotyrosine (4G10)
mAb were obtained from Upstate Biotechnology, Inc.; Phorbol
myristate acetate (PMA), ionomycin, and indo-1/AM, from Cal-
biochem; and FITC-conjugated anti-chicken IgM sera, from
Bethyl Laboratories. Propidium iodide and EGTA were pur-
chased from Sigma-Aldrich.
 
Cells.
 
Parental chicken DT40 cells and Bam32-deficient
DT40 cells were cultured in RPMI 1640 supplemented with
10% heat-inactivated fetal bovine serum (FBS), 1% heat-inacti-
vated chicken serum, 10 U/ml penicillin, 10 
 
 
 
g/ml streptomy-
cin, 2 mM L-glutamine, 1 mM pyruvate, and 50 mM 2-mercap-
toethanol at 37
 
 
 
C and 5% CO
 
2
 
.
 
Generation of Bam32-deficient DT40 Cells.
 
A lamda Zap
DT40 cDNA library was screened by human Bam32 cDNA. The
chicken 
 
Bam32
 
 gene exhibited 
 
 
 
80% identity to human coun-
terpart at the amino acid level. Using the isolated cDNA of
chicken Bam32, a chicken DNA library was screened to obtain
genomic clones. After subcloning, the targeting vectors pBam32-
Neo and pBam32-HisD were made by replacing the genomic
fragment containing exons corresponding to amino acid residues
106–148 with neo- and hisD-cassette (Fig. 1 A). These cassettes
were flanked by 2.5 and 1.8 kb of chicken Bam32 genomic se-
quence on the 5
 
 
 
 and 3
 
 
 
 sides, respectively. Targeting constructs
were sequentially transfected into wild-type DT40 cells by elec-
troporation to obtain null mutants. Selection for drug-resistant
clones was performed using G418 (2 mg/ml) and histidinol (1
mg/ml), and clones were screened by Southern analysis. Evi-
dence for null DT40 mutants was demonstrated by Northern
analysis using the probe containing an entire coding region (Fig.
1 C). No truncated transcripts were observed. Wild-type chicken
 
Bam32 cDNA with a COOH-terminal flanking myc epitopic tag
was cloned into the pApuro vector (8). Bam32-deficient DT40
cells were transfected with this myc-tagged cDNA construct and
selected in the presence of 0.5 
 
 
 
g/ml puromycin (Calbiochem).
Transfection was performed by electroporation at 350V, 960 
 
 
 
F.
 
Measurement of Intracellular Free Calcium.
 
Cells were collected
and resuspended to 10
 
7
 
 cells/ml in RPMI 1640 containing 10%
FBS. After incubation at 37
 
 
 
C for 15 min, Indo-1/AM (7 
 
 
 
g/ml
final concentration) was added, and the cells were incubated for a
further 45 min with resuspension every 15 min. The cells were
centrifuged and resuspended in RPMI 1640 at 2 
 
 
 
 10
 
6
 
 cells/ml.
The cells were stimulated with anti-
 
 
 
 (M4, 2 
 
 
 
g/ml) in the pres-
ence or absence of EGTA (8 mM) and the fluorescence intensity
of intracellular Indo-1 was monitored and analyzed using a BD
LSR system (Becton Dickinson).
 
Western Blot Analysis.
 
Unstimulated or stimulated cells (5 
 
 
 
10
 
6
 
) were lysed in 100 
 
 
 
l RIPA lysis buffer (50 mM Tris pH 7.4,
150 mM NaCl, 10 mM Na
 
4
 
P
 
2
 
O
 
7
 
, 25 mM sodium 
 
 
 
-glycero-
phosphate, 1 mM EDTA, 1% [wt/vol] NP-40, 0.5% [wt/vol] so-
dium deoxycholate, 0.1% [wt/vol] SDS, 1 mM PMSF, 1 mM
Na
 
3
 
VO
 
4
 
, 10 
 
 
 
M E-64, 1 
 
 
 
g/ml pepstatin, 10 
 
 
 
g/ml aprotinin,
10 
 
 
 
g/ml leupeptin). After incubation on ice for 30 min, cell ly-
sates were centrifuged at 16,000 
 
g
 
 for 15 min at 4
 
 
 
C. Lysates were
then denatured in an equal volume of 2
 
 
 
 SDS sample buffer, re-
solved by 10% or 12.5% SDS-PAGE and electrotransfered to ni-
trocellulose membranes in non-SDS–containing transfer buffer
(25 mM Tris, 0.2 M glycine, 20% methanol, pH 8.5). Western
blotting was performed with the following primary Abs and indi-
cated dilutions: anti-p-ERK (1:1,000), anti-ERK (1:1,000), anti-
p-JNK (1:1,000), anti-JNK1 (1 
 
 
 
g/ml), anti-p-p38 MAPK (1:1,000),
anti-p38 MAPK (0.25 
 
 
 
g/ml), anti-p-Akt (1:1,000), anti-p-GSK-
3
 
 
 
/
 
 
 
 (1:1,000), anti-p-Mek1/2 (1:1,000), and anti-Akt (1:1,000)
sera, and anti-p-Raf-1 mAb (1 
 
 
 
g/ml) followed by 1:15,000
anti–rabbit horseradish peroxidase (HRP)-conjugated IgG (Jack-
son ImmunoResearch Laboratories) and 1:2,000 anti–mouse
HRP-conjugated IgG (Santa Cruz Biotechnology, Inc.). Blots
were developed with a Renaissance
 
®
 
 Western blot chemilumi-
nescence reagent (NEN Life Science Products).
 
Luciferase Assays.
 
Cells (1 
 
 
 
 10
 
7
 
) were transfected by elec-
troporation with either NF-AT- (gift from Dr. Gary Koretzky,
University of Pennsylvania, Philadelphia, PA) or NF-
 
 
 
B-
luciferase reporter constructs (pGL2–4 
 
 
 
 NF-
 
 
 
B/tk) as described
(9). After 18–20 h, cells were harvested and plated in 96-well
plates at 2 
 
 
 
 10
 
5
 
/well. Triplicate cultures were incubated in me-
dia alone, with graded dose of M4 mAb or with 50 nM PMA and
2.5 
 
 
 
M ionomycin. After 6 h, cells were lysed in 50 
 
 
 
l reporter
lysis buffer (Promega) for 15 min at room temperature. Luciferase
activity was assayed by adding 20 
 
 
 
l luciferase substrate (Promega)
to 50 
 
 
 
l lysate and immediately measuring with a TD-20/20 Lu-
minometer (Turner Designs). To control for transfection effi-
ciency, the relative luciferase activity of medium and BCR stimu-
lation was calculated relative to PMA/ionomycin stimulation.
 
Flow Cytometric Analysis.
 
For DNA content analysis, cells
(5 
 
 
 
 10
 
5
 
) were cultured with or without anti-
 
 
 
 (M4, 10 
 
 
 
g/ml)
in RPMI 1640 supplemented with 10% heat-inactivated FBS, 1%
heat-inactivated chicken serum, 10 U/ml penicillin, 10 
 
 
 
g/ml
streptomycin, 2 mM L-glutamine, 1 mM pyruvate, and 50 mM
2-mercaptoethanol at 37
 
 
 
C and 5% CO
 
2
 
. After 24 h, cells were
pelleted and resuspended in hypotonic DNA staining solution (50
 
 
 
g/ml propidium iodide, 0.1% sodium citrate, 0.1% Triton
X-100). Samples were kept at 4
 
 
 
C overnight, and then analyzed
with a FACScan™ (Becton Dickinson). For cell surface expression
of BCR, DT40 cells were washed, incubated with FITC-conju- 
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gated anti–chicken IgM sera, and analyzed using a FACScan™.
The x and y axes for the histograms indicate fluorescence intensity
(four-decade log scales) and relative cell number, respectively.
 
Results and Discussion
 
Generation of Bam32-deficient DT40 Cells.
 
To disrupt
the 
 
Bam32
 
 locus in DT40 cells, we transfected a targeting
construct into parental DT40 cells (Fig. 1 A). Screening by
Southern analysis identified two independent clones (M80–
11 and M82–5) that successfully underwent homologous
recombination at both 
 
Bam32
 
 loci (Fig. 1 B). Lack of
Bam32 expression was confirmed by Northern analysis
(Fig. 1 C). We could not detect endogenous Bam32 pro-
tein in either wild-type or mutant DT40 cells, perhaps be-
cause the levels of endogenous Bam32 protein are relatively
low. Flow cytometric analysis showed that surface IgM ex-
pression on both Bam32
 
 
 
/
 
 
 
 cells was almost similar to that
of wild-type cells (Fig. 1 D). BCR cross-linking rapidly in-
duces tyrosine phosphorylation on a number of cellular
proteins. However, after anti–chicken IgM stimulation
there was no obvious difference between wild-type and
Bam32
 
 
 
/
 
 
 
 cells in the overall pattern of new protein tyro-
sine phosphorylation (data not shown).
 
Role of Bam32 in BCR-induced Ca
 
2
 
 
 
 Mobilization and Ty-
rosine Phosphorylation of PLC
 
 
 
2.
 
As BCR-induced cal-
cium mobilization is dramatically reduced in both PLC
 
 
 
2-
deficient DT40 cells and B cells from PLC
 
 
 
2-deficient mice
 
(10, 11), we evaluated BCR-induced calcium mobilization
in Bam32
 
 
 
/
 
 
 
 cells. In both Bam32
 
 
 
/
 
 
 
 cells, this response
was partially impaired compared with wild-type cells (Fig. 2
A). BCR-induced calcium response comprises an initial re-
lease phase and a subsequent sustained plateau phase due to
release of Ca
 
2
 
 
 
 from intracellular stores and Ca
 
2
 
 
 
 influx
across the plasma membrane, respectively (12). Pretreatment
of cells with EGTA resulted in almost complete inhibition
of the sustained phase of the calcium response. Under these
conditions, the partial inhibition of BCR-induced calcium
response in Bam32
 
 
 
/
 
 
 
 cells was still observed, suggesting
that Ca
 
2
 
 
 
 release from intracellular stores is defective in
Bam32
 
 
 
/
 
 
 
 cells (Fig. 2 B). We also confirmed that thapsi-
gargin-sensitive calcium stores are normal in Bam32
 
 
 
/
 
 
 
 cells
(data not shown). Tyrosine phosphorylation of PLC 2 is re-
quired for an increase in its catalytic activity (13). Tyrosine
phosphorylation of PLC 2 after anti-IgM stimulation was
modestly attenuated in Bam32 /  cells compared with
wild-type cells (Fig. 2, C and D). These results suggest that
Bam32 regulates the activation of PLC 2, but is not essen-
tial for PLC 2 activation upon BCR ligation in DT40 cells.
Bam32 Regulates BCR-induced Activation of MAPK Path-
ways, but Not Akt-related Pathways. Three structurally re-
lated MAPK subfamilies have been described in mamma-
lian cells: the p42 and p44 kinases (ERKs), the JNKs, and
the p38 MAPK family (14). Different patterns of activation
of MAPKs may well direct B cells to different cell fates
such as proliferation, differentiation, and apoptosis. In addi-
Figure 1. Disruption of the
Bam32 gene in chicken DT40 B
cells. (A) Partial restriction map
of chicken Bam32 locus and ex-
pected structure of the targeted
Bam32 alleles. The restriction
endonuclease cleavage sites are
abbreviated: X, XbaI; E, EcoRI.
(B) Southern analysis of genomic
DNA from wild-type DT40 cells
(lane 1), neo-targeted cells
( / , lane 2), and neo- and
hisD-targeted cells ( / , lane 3
and 4). Xba I-digested genomic
DNA separated on an agarose gel
was blotted and hybridized with
a chicken Bam32 DNA probe
shown in A. Wild-type (WT)
and targeted alleles show 15.5-
or 5.0-kb fragments, respec-
tively. (C) Northern analysis us-
ing a chicken cDNA probe for
Bam32 (top) and  -actin (bot-
tom). Wild-type (WT) DT40
cells contain a hybridizable RNA
species of  3,000 nucleotides.
(D) Cell surface expression of
BCR. BCR expression on the
surface of wild-type (WT) and
two independent Bam32-defi-
cient (M80–11, M82–5) DT40
cells was analyzed by flow cy-
tometry. Unstained cells were
used as negative controls.146 Bam32 Regulates BCR Signaling and Cell Survival
tion, PLC 2 is required for full activation of all three
MAPKs in DT40 B cells (15). Thus, we tested whether the
phosphorylation of these MAPKs could be affected by the
absence of Bam32 (Fig. 3 A). The kinetic profile of activa-
tion of the three MAPKs after anti-IgM stimulation of
wild-type DT40 cells was consistent with our previous
findings (15, 16). In Bam32 /  cells, the phosphorylation
of JNK1 was consistently reduced by  85% compared
with wild-type cells. In addition, the phosphorylation of
both ERK2 and p38 MAPK was partially impaired in
Bam32 /  cells. These findings are consistent with studies
showing that JNK activation is drastically attenuated either
Figure 2. Impairment of BCR-induced Ca2  mobilization and tyrosine phosphoryla-
tion of PLC 2 in the absence of Bam32. (A) Ca2  mobilization in wild-type (WT)
DT40 cells, and Bam32-deficient clones (M80–11, M82–5). Intracellular free calcium
levels in Indo-1–loaded cells were monitored using a BD LSR system, after cells were
stimulated with M4 mAb to chicken   chain (2  g/ml). (B) Intracellular Ca2  release in
the presence of EGTA. (C) Tyrosine phosphorylation of PLC 2. At the indicated time
points after BCR stimulation (M4, 5  g/ml), immunoprecipitates with anti-PLC 2 Ab were separated on a 10% SDS-PAGE gel, and were analyzed by
Western blotting with biotinated anti-phosphotyrosine mAb (top,  pY) or anti-PLC 2 Ab (bottom,  PLC 2). (D) Densitometrical analyses of tyrosine
phosphorylation of PLC 2. The resulting values were expressed as the percentage in reference to that of maximal response in BCR-stimulated wild-type
DT40 cells. The results were shown by average and SEM of three independent experiments.
Figure 3. BCR-induced acti-
vation of MAPK and Akt path-
ways in wild-type and Bam32-
deficient DT40 cells. (A) Cells
were stimulated with anti- 
(M4, 5  g/ml) for indicated time
periods. Cell lysates were subse-
quently separated on a 10% SDS-
PAGE gel, and were analyzed by
Western blotting with anti-phos-
pho-ERK, anti-phospho-JNK,
anti-phospho-p38 MAPK, anti-
phospho-Akt, anti-phospho-
GSK-3, and anti-Akt sera. (B)
Densitometrical analyses of BCR-
induced activation of MAPK.
The resulting values were ex-
pressed as the percentage in refer-
ence to that of maximal response
in BCR-stimulated wild-type
DT40 cells. The results were
shown by average and SEM of
three independent experiments.
(C) Cells were stimulated as de-
scribed in A. Cell lysates were
subsequently separated on a 10%
SDS-PAGE gel, and were ana-
lyzed by Western blotting with
anti-phospho-Raf-1 mAb, and
anti-phospho-Mek sera.147 Niiro et al. Brief Definitive Report
appears to regulate MAPK-family kinases and especially
JNK but not the PI3K-regulated kinases Akt and GSK-3.
Role of Bam32 in BCR-induced Activation of NF-AT and
NF- B. BCR cross-linking leads to the activation of two
pivotal transcription factors NF-AT and NF- B in B cells.
The absence of either of these transcription factors leads to
significant defects in B cell functions (20, 21). BCR-induced
NF-AT activation is almost completely blocked in both
PLC 2- and IP3R-deficient DT40 cells (22), consistent
with the crucial role of calcium in the activation of NF-AT.
Anti-IgM stimulation caused a dose-dependent induction of
NF-AT activation in wild-type cells (Fig. 4, top panel). This
activation was significantly attenuated in both Bam32 / 
cell lines. BCR-induced NF- B activation is almost com-
pletely eliminated either in PLC 2-deficient DT40 cells or
by blocking BCR-induced calcium mobilization in wild-
type DT40 cells with EGTA/BAPTA-AM (23). Anti-IgM–
induced activation of NF- B was only partially blocked in
Bam32 /  cells (Fig. 4, bottom panel). Notably, the level of
NF-AT inhibition was consistently more pronounced than
that of NF- B inhibition in Bam32 /  cells.
Figure 4. Impairment of BCR-induced NF-AT and NF- B activation
in the absence of Bam32. Cells transfected with NF-AT (top) or NF- B
(bottom) luciferase reporter construct were stimulated with graded dose
of anti-  (M4) for 6 h, lysed, and luciferase activity was assayed using a
luminometer. The relative luciferase activity of medium and BCR stimu-
lation was expressed in reference to that of PMA/ionomycin stimulation.
The results were shown by average and SEM of triplicate cultures. One
experiment representative of four independent experiments is shown.
by blocking intracellular calcium release of wild-type B
cells treated with BAPTA-AM or in inositol 1,4,5-triphos-
phate receptor (IP3R)-deficient B cells (15, 16). The fact
that the activation of all three MAPKs was affected suggests
again a role for Bam32 in BCR-induced PLC 2 activation.
While the activation of MAPKs and calcium mobilization
have been well studied in DT40 cells, PI3K activation has
only been recently examined. Mice deficient in the gene en-
coding the regulatory p85 subunit of PI3K have profound
defects in B cell proliferative responses and B cell survival
(see references 1 and 3). PI3K plays a role in BCR signaling
via generation of a key second messenger PI(3,4,5)P3 which
in turn recruits a number of PH domain-containing signal-
ing molecules to the vicinity of BCR signaling complex.
Bam32 is recruited to the plasma membrane upon BCR ac-
tivation in a PI3K-dependent manner (4). Thus, we tested if
the absence of Bam32 affected PI3K-regulated molecules,
and in particular Akt, as Akt activation is crucial for DT40
cell survival (17). However, the phosphorylation of Akt after
anti-IgM stimulation was not altered in Bam32 /  cells (Fig.
3 A). This is consistent with the fact that decreasing level of
Ca2  release does not affect Akt activation in DT40 cells
(18). GSK-3 is a critical downstream element of Akt path-
way, and can be regulated by Akt-mediated phosphorylation
(19). Like Akt, the phosphorylation of GSK-3 was not af-
fected in Bam32 /  cells (Fig. 3 A). In summary, Bam32
Figure 5. Induction of apoptosis in wild-type and Bam32-deficient
DT40 cells. (A) Wild-type cells (WT), Bam32-deficient clones (M80–11,
M82–5), and Bam32-deficient clones expressing wild-type Bam32 were
cultured with or without anti-  (M4, 10  g/ml) for 24 h, treated in hy-
potonic DNA staining solution containing 50  g/ml propiduim iodide,
and subjected to analysis by FACScan™. The percentage of fragmented
nuclei is indicated. (B) The expression of chicken Bam32 transgene. Cell
lysates were separated on a 12.5% SDS-PAGE gel, and analyzed by West-
ern blotting with anti-Myc mAb (0.5  g/ml).148 Bam32 Regulates BCR Signaling and Cell Survival
Bam32 Regulates BCR-induced Cell Death. BCR cross-
linking leads to growth inhibition and apoptosis in imma-
ture B cell lines including DT40 cells. Treatment of wild-
type DT40 cells for 24 h after anti-IgM stimulation results
in a significant increase in apoptotic cells (Fig. 5). In both
PLC 2- and IP3R-deficient DT40 cells, this BCR-induced
apoptotic response is significantly decreased (22). In con-
trast, both Bam32 /  cell lines were much more suscepti-
ble to BCR-induced cell death (Fig. 5). As expected, trans-
fection of chicken Bam32 cDNA into Bam32-deficient
DT40 cells restored cells to a wild-type phenotype.
How might Bam32 promote B cell survival? In consid-
ering this question it is useful to compare the phenotypes of
Bam32 /  cells, where BCR-induced death is increased, to
that of PLC 2 /  and IP3R /  cells, where BCR-induced
cell death is greatly attenuated (10, 22). Either a change in a
BCR-induced death pathway or a BCR-induced survival
pathway could account for this difference. As JNK is not
activated in Bam32 /  cells (Fig. 3 A) or in PLC 2 /  and
IP3R /  cells (15), JNK is an unlikely candidate for
regulating BCR-induced death. However, BAPTA-AM,
which chelates intracellular free calcium ([Ca2 ]i), blocks
BCR-induced apoptosis in DT40 cells (16), and after BCR
ligation PLC 2 /  and IP3R /  cells neither release
[Ca2 ]i nor die (10, 22). As [Ca2 ]i is essential for BCR-
induced death, it is likely that the partial release of calcium
in Bam32 /  cells (Fig. 2 A) is sufficient to induce a cell
death pathway not activated in PLC 2 /  and IP3R /  cells.
The release of [Ca2 ]i alone does not explain why
Bam32 /  cells are more susceptible to BCR-induced
death than wild-type cells (Fig. 5). Here the difference may
be due to a deficiency in Bam32 /  cells of a BCR-induced
survival pathway. Three candidate pathways come to mind.
The first candidate is the Raf/Mek/ERK pathway. Sev-
eral lines of evidence suggest that this pathway has an im-
portant role in modulating cell survival (24). In addition to
partial inhibition of ERK2 activation in Bam32 /  cells,
Mek activation was significantly inhibited (Fig. 3 C). How-
ever, specific Mek inhibitors do not block BCR-induced
apoptosis in the WEHI-231 line (25). And the same is true
in DT40 cells (data not shown). Recent papers also showed
that disruption of the Raf-1 gene results in a hyperapoptotic
phenotype without affecting Mek-ERK activation (26,
27). Thus, Raf-1 might provide a survival signal indepen-
dent of Mek-ERK activation. Raf-1 requires phosphoryla-
tion of the serine at position 338 (S338) for activation (28).
Interestingly, BCR-induced Raf-1 phosphorylation at
S338 is more significantly inhibited in Bam32 /  cells than
ERK activation (Fig. 3 C). Thus, reduced Raf-1 activation
may contribute to elevating death in Bam32 /  cells and
Raf-1 may play a role in B cell survival.
A second candidate for regulating cell survival is the NF-
 B pathway. A number of anti-apoptotic proteins includ-
ing Bcl-2 are upregulated by the transcription factor NF-
 B (29). And Bam32 /  cells do have a partial reduction in
BCR-induced NF- B activation (Fig. 4).
A third candidate for regulating cell survival is the PI3K
pathway, known to play a key role in B cell survival (1).
Disruption of the gene encoding a novel B cell adaptor for
PI3K activation (BCAP) results in inhibition of BCR-
induced PI3K activation and also a hyperapoptotic pheno-
type (30). Likewise, treatment of DT40 cells with a PI3K
inhibitor, LY294002, drastically accelerates BCR-induced
cell death (data not shown). Therefore, molecules down-
stream of PI3K clearly play a role in B cell survival. The
Akt kinase is an obvious candidate because inactivation of
both Akt alleles leads to death of DT40 cells (17). Our data
suggest that Bam32 does not regulate an Akt-dependent
pathway. However, it remains possible that Bam32 regu-
lates other PI3K-regulated molecules affecting B cell sur-
vival. In this context, Vav-Rac pathway is a compelling
possibility, because this pathway not only regulates [Ca2 ]i
and JNK activation but also cell death independent of
PLC 2 activation (31). Whether Bam32 regulates the Vav-
Rac pathway remains to be elucidated.
In summary, our results suggest that Bam32 may normally
function to regulate the fate of B cells triggered by antigen
through the BCR complex. BCR ligation promotes the
survival of GC B cells (32). Bam32 is expressed at high lev-
els in GC B cells and upregulated after CD40 ligation (4).
The increased levels of Bam32 in CD40-triggered GC B
cells could facilitate the survival of B cells selected by anti-
gen in the GCs during T cell–dependent immune responses.
We thank Drs. Aaron J. Marshall and Andrew Craxton and Mr.
Aimin Jiang for valuable discussions.
This work was supported by National Institutes of Health grants
AI 45088 and RR00166 and by grants from the Japanese Ministry
of Education, Science, Sports and Culture.
Submitted: 31 August 2001
Revised: 26 October 2001
Accepted: 12 November 2001
References
1. Marshall, A.J., H. Niiro, T.J. Yun, and E.A. Clark. 2000.
Regulation of B-cell activation and differentiation by the
phosphatidylinositol 3-kinase and phospholipase C  path-
ways. Immunol. Rev. 176:30–46.
2. Benschop, R.J., and J.C. Cambier. 1999. B cell develop-
ment: signal transduction by antigen receptors and their sur-
rogates. Curr. Opin. Immunol. 11:143–151.
3. Kurosaki, T. 1999. Genetic analysis of B cell antigen receptor
signaling. Annu. Rev. Immunol. 17:555–592.
4. Marshall, A.J., H. Niiro, C.G. Lerner, T.J. Yun, S. Thoma,
C.M. Disteche, and E.A. Clark. 2000. A novel B lympho-
cyte-associated adaptor protein, Bam32, regulates antigen
receptor signaling downstream of phosphatidylinositol
3-kinase. J. Exp. Med. 191:1319–1331.
5. Dowler, S., R.A. Currie, C.P. Downes, and D.R. Alessi.
1999. DAPP1: a dual adaptor for phosphotyrosine and
3-phosphoinositides. Biochem. J. 342:7–12.
6. Rao, V.R., M.N. Corradetti, J. Chen, J. Peng, J. Yuan, G.D.
Prestwich, and J.S. Brugge. 1999. Expression cloning of pro-
tein targets for 3-phosphorylated phosphoinositides. J. Biol.
Chem. 274:37893–37900.
7. Ishiai, M., M. Kurosaki, R. Pappu, K. Okawa, I. Ronko, C.
Fu, M. Shibata, A. Iwamatsu, A.C. Chan, and T. Kurosaki.149 Niiro et al. Brief Definitive Report
1999. BLNK required for coupling Syk to PLC 2 and Rac1-
JNK in B cells. Immunity. 10:117–125.
8. Takata, M., H. Sabe, A. Hata, T. Inazu, Y. Homma, T.
Nukada, H. Yamamura, and T. Kurosaki. 1994. Tyrosine ki-
nases Lyn and Syk regulates B cell receptor-coupled Ca2  mo-
bilization through distinct pathways. EMBO J. 13:1341–1349.
9. Berberich, I., G.L. Shu, and E.A. Clark. 1994. Cross-linking
CD40 on B cells rapidly activates nuclear factor-kappa B. J.
Immunol. 153:4357–4366.
10. Takata, M., Y. Homma, and T. Kurosaki. 1995. Requirement
of phospholipase C- 2 activation in surface immunoglobulin
M-induced B cell apoptosis. J. Exp. Med. 182:907–914.
11. Hashimoto, A., K. Takeda, M. Inaba, M. Kekimata, T. Kai-
sho, S. Ikehara, Y. Homma, S. Akira, and T. Kurosaki. 2000.
Essential role of phospholipase C- 2 in B cell development
and function. J. Immunol. 165:1738–1742.
12. Scharenberg, A.M., and J.-P. Kinet. 1998. PtdIns-3,4,5-P3:
A regulatory nexus between tyrosine kinases and sustained
calcium signals. Cell. 94:5–8.
13. Carpenter, G., and Q.-s. Ji. 1999. Phospholipase C-  as a sig-
nal-transducing element. Exp. Cell Res. 253:15–24.
14. Su, B., and M. Karin. 1996. Mitogen-activated protein kinase
cascades and regulation of gene expression. Curr. Opin. Im-
munol. 8:402–411.
15. Hashimoto, A., H. Okada, A. Jiang, M. Kurosaki, S. Green-
berg, E.A. Clark, and T. Kurosaki. 1998. Involvement of
guanosine triphosphatases and phospholipase C- 2 in extra-
cellular signal-regulated kinase, c-jun NH2-terminal kinase,
and p38 mitogen-activated protein kinase activation by the B
cell antigen receptor. J. Exp. Med. 188:1287–1295.
16. Jiang, A., A. Craxton, T. Kurosaki, and E.A. Clark. 1998.
Different protein tyrosine kinases are required for B cell anti-
gen receptor-mediated activation of extracellular signal-regu-
lated kinase, c-jun NH2-terminal kinase 1, and p38 mitogen-
activated protein kinase. J. Exp. Med. 188:1297–1306.
17. Pogue, S.L., T. Kurosaki, J. Bolen, and R. Herbst. 2000. B
cell antigen receptor-induced activation of Akt promotes B
cell survival and is dependent on Syk kinase. J. Immunol. 165:
1300–1306.
18. Craxton, A., A. Jiang, T. Kurosaki, and E.A. Clark. 1999.
Syk and Bruton’s tyrosine kinase are required for B cell anti-
gen receptor-mediated activation of the kinase Akt. J. Biol.
Chem. 274:30644–30650.
19. Srivastava, A.K., and S.K. Pandey. 1998. Potential mecha-
nism(s) involved in the regulation of glycogen synthesis by
insulin. Mol. Cell. Biochem. 182:135–141.
20. Peng, S.L., A.J. Gerth, A.M. Ranger, and L.H. Glimcher.
2001. NFATc1 and NFATc2 together control both T and B
cell activation and differentiation. Immunity. 14:13–20.
21. Reya, T., and R. Grosschedl. 1998. Transcriptional regulation
of B-cell differentiation. Curr. Opin. Immunol. 10:158–165.
22. Sugawara, H., M. Kurosaki, M. Takata, and T. Kurosaki. 1997.
Genetic evidence for involvement of type 1, type 2 and type 3
inositol 1,4,5-triphosphate receptors in signal transduction
through the B-cell antigen receptor. EMBO J. 16:3078–3088.
23. Petro, J.R., and W.N. Khan. 2001. Phospholipase C- 2 cou-
ples Bruton’s tyrosine kinase to the NF-kB signaling pathway
in B lymphocytes. J. Biol. Chem. 276:1715–1719.
24. Bonni, A., A. Brunet, A.E. West, S.R. Datta, M.A. Takasu,
and M.E. Greenberg. 1999. Cell survival promoted by the
Ras-MAPK signaling pathway by transcription-dependent
and -independent mechanisms. Science. 286:1358–1362.
25. Richards, J.D., S.H. Davé, C.-H.G. Chou, A.A. Mamchak,
and A.L. DeFranco. 2001. Inhibition of the MEK/ERK sig-
naling pathway blocks a subset of B cell response to antigen.
J. Immunol. 166:3855–3864.
26. Hüser, M., J. Luckett, A. Chiloeches, K. Mercer, M. Iwobi,
S. Giblett, X.-M. Sun, J. Brown, R. Marais, and C. Prit-
chard. 2001. MEK kinase activity is not necessary for Raf-1
function. EMBO J. 20:1940–1951.
27. Mikula, M., M. Schreiber, Z. Husak, L. kucerova, J. Rüth,
R. Wieser, K. Zatloukal, H. Beug, E.F. Wagner, and M.
Baccarini. 2001. Embryonic lethality and fetal liver apoptosis
in mice lacking the c-raf-1 gene. EMBO J. 20:1952–1962.
28. Diaz, B., D. Barnard, A. Filson, S. MacDonald, A. King, and
M. Marshall. 1997. Phosphorylation of Raf-1 serine 338-serine
339 is an essential regulatory event for Ras-dependent activa-
tion and biological signaling. Mol. Cell. Biol. 17:4509–4516.
29. Grossmann, M., L.A. O’Reilly, R. Gugasyan, A. Strasser, J.M.
Adams, and S. Gerondakis. 2000. The anti-apoptotic activities
of Rel and RelA required during B-cell maturation involve
the regulation of Bcl-2 expression. EMBO J. 19:6351–6360.
30. Okada, T., A. Maeda, A. Iwamatsu, K. Gotoh, and T. Kuro-
saki. 2000. BCAP: The tyrosine kinase substrate that con-
nects B cell receptor to phosphoinositide 3-kinase activation.
Immunity. 13:817–827.
31. Bustelo, X.R. 2000. Regulatory and signaling properties of
the Vav family. Mol. Cell. Biol. 20:1461–1477.
32. Liu, Y.J., D.E. Joshua, G.T. Williams, C.A. Smith, J. Gor-
don, and I.C. MacLennan. 1989. Mechanism of antigen-
driven selection in germinal centres. Nature. 342:929–931.